Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CQA 206-291
- Development stage
- Discontinued
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CQA 206-291 is a **novel ergoline derivative** and small molecule drug developed as a dopamine agonist for the treatment of Parkinson's disease. It was investigated for both de novo and levodopa-treated Parkinson's patients, where it showed significant antiparkinsonian activity with an effective dose range of 5–30 mg/day. The compound has a mixed D1-D2 dopaminergic receptor agonist profile—described as having both **dopamine agonist and antagonist-agonist (dualistic) properties**. Adverse events were similar to those of other dopamine agonists and typically mild and transient. Despite promising efficacy, development was discontinued due to laboratory-based toxicity concerns, and the drug is no longer in development for clinical use[1][3][5][7][9].
- Other names
- CQA 206-291CQA206-291CQA-206-291CQA-206CQA206CQA 206
02
Targets
DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on CQA 206-291.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CQA 206-291.